Edition:
India

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

8.75USD
2:29am IST
Change (% chg)

$-0.75 (-7.89%)
Prev Close
$9.50
Open
$9.55
Day's High
$9.75
Day's Low
$8.60
Volume
116,153
Avg. Vol
130,938
52-wk High
$20.00
52-wk Low
$3.00

Latest Key Developments (Source: Significant Developments)

Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Calithera Biosciences Inc :Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting.Calithera Biosciences Inc - ‍expanding Bristol-Myers Squibb clinical collaboration​.Calithera Biosciences Inc - ‍expanded its existing clinical collaboration with Bristol-Myers Squibb, evaluating CB-839 in combination with opdivo​.Calithera Biosciences Inc - ‍analysis of all safety evaluable patients demonstrated CB-839 was well tolerated when combined with opdivo​.Calithera Biosciences - ‍among 16 evaluable melanoma patients, one patient achieved a complete response and two patients achieved partial responses​.Calithera Biosciences Inc - ‍study will be expanded to enroll additional melanoma patients​.Calithera Biosciences Inc - ‍as part of expanded collaboration, melanoma development costs will be shared​.  Full Article

Calithera Biosciences Q3 operating loss per share $0.17
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Calithera Biosciences Inc :Calithera biosciences reports third quarter 2017 financial results and recent highlights.Q3 operating loss per share $0.17.Q3 revenue $7.3 million.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.5 million -- Thomson Reuters I/B/E/S.Calithera biosciences inc - ‍as of september 30, 2017, cash, cash equivalents and investments totaled $196.5 million​.Calithera biosciences inc - qtrly ‍research and development expenses were $10.8 million compared with $6.3 million for same period in prior year​.  Full Article

Hawkes Bay Master Investors (Cayman) L.P. reports 5.28 pct passive stake in Calithera Biosciences Inc
Monday, 6 Mar 2017 

Calithera Biosciences Inc :Hawkes Bay Master Investors (Cayman) L.P. reports 5.28 percent passive stake in Calithera Biosciences Inc as on February 22, 2017 - SEC filing.  Full Article

Calithera Biosciences says CFO William Waddill has resigned
Monday, 12 Dec 2016 

Calithera Biosciences Inc : Calithera biosciences - William Waddill has resigned as company's senior vice president and chief financial officer .Waddill's resignation will be effective on or about December 31, 2016.  Full Article

Calithera Biosciences Q2 loss per share $0.55
Wednesday, 10 Aug 2016 

Calithera Biosciences Inc : Calithera Biosciences reports second quarter 2016 financial results and recent highlights . Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.55.  Full Article

Calithera Biosciences reports Q1 loss per share $0.52
Wednesday, 11 May 2016 

Calithera Biosciences Inc :Qtrly loss per share $0.52.  Full Article

BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb

* Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting